IRIS
MASSIMINO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.359
EU - Europa 3.559
AS - Asia 2.635
SA - Sud America 548
AF - Africa 416
Continente sconosciuto - Info sul continente non disponibili 201
OC - Oceania 7
Totale 12.725
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.165
SG - Singapore 1.320
RU - Federazione Russa 1.100
IT - Italia 1.027
CN - Cina 571
BR - Brasile 463
IE - Irlanda 338
VN - Vietnam 246
CI - Costa d'Avorio 232
UA - Ucraina 225
IN - India 157
DE - Germania 149
CA - Canada 140
FR - Francia 125
NL - Olanda 106
SE - Svezia 102
BE - Belgio 101
GB - Regno Unito 89
BD - Bangladesh 81
SN - Senegal 77
KR - Corea 62
FI - Finlandia 50
NG - Nigeria 50
PL - Polonia 34
AR - Argentina 30
MX - Messico 28
ES - Italia 27
IQ - Iraq 26
JP - Giappone 21
UZ - Uzbekistan 20
ZA - Sudafrica 20
TR - Turchia 19
HK - Hong Kong 18
CZ - Repubblica Ceca 16
CO - Colombia 15
GR - Grecia 14
EC - Ecuador 13
IR - Iran 13
CH - Svizzera 12
ID - Indonesia 10
SA - Arabia Saudita 10
KE - Kenya 9
MA - Marocco 9
PK - Pakistan 9
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
AT - Austria 8
TN - Tunisia 8
PY - Paraguay 7
AU - Australia 6
IL - Israele 6
JM - Giamaica 6
TT - Trinidad e Tobago 6
BG - Bulgaria 5
EG - Egitto 5
HU - Ungheria 5
KZ - Kazakistan 5
LB - Libano 5
PH - Filippine 5
RS - Serbia 5
AZ - Azerbaigian 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
MY - Malesia 4
NO - Norvegia 4
PE - Perù 4
RO - Romania 4
UY - Uruguay 4
BJ - Benin 3
KG - Kirghizistan 3
LT - Lituania 3
BO - Bolivia 2
HR - Croazia 2
LK - Sri Lanka 2
OM - Oman 2
PR - Porto Rico 2
SI - Slovenia 2
TH - Thailandia 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
DZ - Algeria 1
GA - Gabon 1
GD - Grenada 1
IS - Islanda 1
JO - Giordania 1
LV - Lettonia 1
MN - Mongolia 1
NA - Namibia 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NP - Nepal 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
SV - El Salvador 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.525
Salva come PNG Salva come JPEG
Città #
Singapore 826
Santa Clara 750
Dallas 723
Moscow 523
Chandler 443
San Jose 363
Dublin 338
Ashburn 312
Chicago 295
Catania 256
Abidjan 232
Jacksonville 220
Los Angeles 137
Boardman 126
Beijing 119
Kochi 104
Cambridge 93
Lauterbourg 92
Lawrence 91
Andover 87
Nanjing 82
New York 77
Dakar 76
Hefei 69
Toronto 67
Grafing 64
Hanoi 64
Rotterdam 64
Ho Chi Minh City 62
Seoul 61
Civitanova Marche 59
Council Bluffs 58
Palermo 52
Milan 50
São Paulo 50
Wingene 50
Des Moines 48
Wilmington 46
San Mateo 43
Buffalo 40
Orem 34
Montreal 33
Munich 30
Rome 28
Dong Ket 27
Warsaw 27
Brussels 26
The Dalles 23
Abuja 22
Bari 22
Turku 22
Columbus 21
Lagos 21
Ottawa 21
San Giovanni la Punta 21
Seattle 20
Tokyo 20
Johannesburg 18
Hebei 17
Lappeenranta 17
Nanchang 17
Phoenix 17
Rio de Janeiro 17
Shenyang 17
Chennai 16
Jiaxing 16
London 16
Denver 15
Falls Church 15
Frankfurt am Main 15
Houston 15
Messina 15
Saint Petersburg 15
Belo Horizonte 14
Brooklyn 14
Hong Kong 14
Aci Catena 13
Atlanta 13
Boston 13
Changsha 13
Baghdad 12
Bremen 12
Manchester 12
Poplar 12
Santa Venerina 12
Brasília 11
Brno 11
Helsinki 11
Nijmegen 11
San Francisco 11
Stockholm 11
Tashkent 11
Amsterdam 10
Dhaka 10
Haiphong 9
Izegem 9
Mexico City 9
Pune 9
Tianjin 9
Washington 9
Totale 8.293
Salva come PNG Salva come JPEG
Nome #
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 255
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells 239
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 229
Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series 213
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 212
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 196
A novel and selective sigma-1/2 receptor ligand (PO680C): Binding properties and expression of tissue transglutaminase 192
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 185
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 183
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop 174
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 172
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 172
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 166
Comparative proteomic analysis of insulin receptor isoform A and B signaling 165
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 165
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 163
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 163
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 163
A novel and selective σ1/2 receptor ligand (PO680C): binding properties and expression of tissue transglutaminase 160
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 160
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 159
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 158
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 157
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 153
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 151
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 151
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 150
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 150
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 148
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas 147
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 146
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 145
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 144
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 143
New insights in thyroid cancer and p53 family proteins 143
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release 141
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 140
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 139
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 139
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state 136
Opportunities and challenges of liquid biopsy in thyroid cancer 133
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 133
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 132
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 131
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 130
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 130
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 129
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 126
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 122
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 121
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 121
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 119
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy 119
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 119
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 118
Computational and experimental characterization of critical amino acidic residues in the BCR-ABL kinase domain explaining TKIs resistance in patients with chronic myeloid leukemia 117
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 116
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 114
Uncommon long-term survival in a patient with chronic myeloid leukemia 112
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 112
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 111
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 110
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 103
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 101
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 96
UNFAVOURABLE OUTCOME OF CML PATIENTS CARRYING COMPLEX VARIANT CHROMOSOMAL TRANSLOCATIONS TREATED WITH TYROSINE KINASE INHIBITORS 96
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 96
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 94
REThinking the role of the RET oncogene in breast cancer 91
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 91
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 90
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 89
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 89
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 89
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series 88
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 87
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 87
Ruolo delle IAPs e di Smac/DIABLO nella resistenza ai farmaci antiblastici di cellule di carcinoma indifferenziato della tiroide 87
Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report 84
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 83
Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines 82
High BCR-ABL expression levels at diagnosis may predict unfavorable CML responses to Imatinib therapy 82
EFFICACY OF IMATINIB MESYLATE ON CHRONIC PHASE CML PATIENTS ACCRUED IN THE SCREEN MULTICENTER STUDY: INTERIM REPORT ON THE FIRST 193 CASES 80
Experimental and Computational Characterization of Amino Acidic Residues in the BCR-ABL kinase domain contributing to TKI resistance in patients with Chronic Myeloid Leukemia 78
L’attività tirosin-chinasica di BCR/Abl modula l’espressione di IRF-5 78
Computational and biological characterization of nuclear import/export signals of the human BCR protein 78
SYNTHESIS OF BNIT AN ISOTHIOCYANATE DERIVATIVE OF N-BENZYL-NORMETAZOCINE AS ACYLANT AGENT FOR σ1 RECEPTOR 77
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib 77
Molecular dynamics simulations reveal the role of five BCR-ABL kinase domain critical residues in TKIS binding 76
Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer 76
High BCR-ABLIS expression at diagnosis and after 3 and 6 months of treatment are associated with unfavourable responses to Imatinib 75
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 74
HIGH BCR-ABL LEVELS AT DIAGNOSIS ARE ASSOCIATED WITH UNFAVORABLE RESPONS- ES TO IMATINIB 74
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 74
THE SCREEN PROJECT: A CML DATA REGISTRY IN SICILY AND CALABRIA 71
RAPID RESPONSE TO DASATINIB IN A CML BLAST CRISIS PATIENT THAT SUBSEQUENTLY DEVELOPED SEQUENTIAL BCR-ABL MUTATIONS CAUSING MULTI-DRUG RESISTANCE: A CASE REPORT 69
SINTESI E VALUTAZIONE FARMACOLOGICA DI DERIVATI METIL 2-[(4-BENZILPIPERIDIN-1-IL)METIL]-1-FENIL-CICLOPROPANCARBOSSILATO COME LIGANDI SIGMA AD ALTA AFFINITÀ 69
IRF5 promotes the proliferation of human thyroid cancer cells. 68
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 68
Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor 65
Totale 12.474
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.111
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.111
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022632 0 97 15 9 112 13 103 27 52 14 35 155
2022/20231.373 106 102 43 153 91 214 19 263 289 11 50 32
2023/2024766 57 107 30 36 32 184 11 44 7 35 133 90
2024/20252.956 111 445 116 175 585 394 191 80 187 203 315 154
2025/20265.465 300 272 790 377 815 1.290 583 109 307 319 189 114
2026/2027331 206 125 0 0 0 0 0 0 0 0 0 0
Totale 12.725